Statements (40)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:ATCCode |
A07DA06
|
| gptkbp:bioavailability |
1%
|
| gptkbp:CASNumber |
gptkb:864821-90-9
|
| gptkbp:contraindication |
alcoholism
pancreatitis biliary duct obstruction patients without a gallbladder |
| gptkbp:drugClass |
gastrointestinal agent
|
| gptkbp:eliminationHalfLife |
3.7-6 hours
|
| gptkbp:excretion |
feces
|
| gptkbp:hasInChIKey |
QJQYJQFZJXOMFQ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C32H35N5O5
|
| gptkbp:hasSMILES |
CC(C)C1=CC2=C(C=C1)N=C(N2)N3CCN(CC3)C(=O)C4=CC=CC=C4C(=O)N5CCN(CC5)C(=O)C6=CC=CC=C6
|
| gptkbp:hasUNII |
6T4D8K0UQ7
|
| https://www.w3.org/2000/01/rdf-schema#label |
DB08930
|
| gptkbp:indication |
treatment of irritable bowel syndrome with diarrhea (IBS-D)
|
| gptkbp:legalStatus |
prescription only
patented |
| gptkbp:manufacturer |
gptkb:Allergan
gptkb:Actavis |
| gptkbp:mechanismOfAction |
mixed mu-opioid receptor agonist, delta-opioid receptor antagonist, kappa-opioid receptor agonist
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
569.65
|
| gptkbp:name |
Eluxadoline
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:proteinBinding |
81%
|
| gptkbp:PubChem_CID |
gptkb:DB08930
11519436 9690550 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
abdominal pain constipation |
| gptkbp:status |
FDA approved
|
| gptkbp:synonym |
Eluxadoline hydrochloride
JNJ-27018966 |
| gptkbp:bfsParent |
gptkb:dolutegravir
|
| gptkbp:bfsLayer |
6
|